66th ASH Annual Meeting: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III

Symposia: Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms Oral and Poster Abstracts
Poster

Research, Antibody Therapy, Acute Myeloid Malignancies, Combination therapy, AML, Fundamental Science, Clinical trials, Apoptosis, Adult, Bispecific Antibody Therapy, Drug development, Translational Research, Assays, Chemotherapy, Clinical Research, Diseases, Immune mechanism, Treatment Considerations, Biological therapies, Immunotherapy, Non-Biological therapies, Metabolism, Computational biology, Biological Processes, Myeloid Malignancies, Technology and Procedures, Molecular biology, Study Population, Multi-systemic interactions, Profiling, Human, Pathogenesis, Animal model, Omics technologies

Halls G-H (San Diego Convention Center)

4134

The Hyperbolic NAMPT Inhibitor RPT1G Synergizes with BCL-2 Family Inhibitors and Helps Overcome Venetoclax Resistance in Acute Myeloid Leukemia Cells

Gregory Crimmins, PhD¹^*, Min Wu, PhD²^*, Francis Roushar, PhD²^*, Claudia F. Ramos Aguilar, BS²^*, Mehdi Gharghabi, PharmD³^*, Banumathi Cole, PhD²^*, Rosa Lapalombella, PhD³ and Dennise A. De Jesús-Díaz, PhD²^*

¹Remedy Plan Therapeutics, GAITHERSBURG, MD
²Remedy Plan Therapeutics, Gaithersburg, MD
³The Ohio State University, Columbus, OH

4135

An Open-Label, Multicenter, Phase Ib Study of the Anti-TIM3 Monoclonal Antibody BC3402 in Combination with Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Bing Li, MD^1,2^*, Qing-song Yin³^*, Xiaojing Yan, MD, PhD⁴, Min Hang⁵^*, Hai-Jun Guo⁵^*, Sheng Wang⁵^*, Yi-wei Wang⁵^*, Yong-jiang Hei⁵^* and Zhi-jian Xiao^1,2^*

¹MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
²State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, China
³Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
⁴Department of Hematology, The First Hospital of China Medical University, Liaoning, China
⁵Biocity Biopharmaceutics Co. Ltd, Wuxi, China

4136

CD74 Antibody Conjugated to an MCL1 Inhibitor (S227928) Combines Synergistically with Venetoclax to Enhance Killing of Acute Myeloid Leukemia

Donia M. Moujalled, PhD^1,2^*, Giovanna Pomilio^1,2^*, Thomas Morley^1,2^*, Veronique Litalien^1,2^*, Natasha S. Anstee, PhD^2,3^*, Sun Loo, MBBS, FRACP, FRCPA^2,3,4, Zhi-Han Yeoh, MBBS^1,2,4^*, Clovis Boibessot, PhD⁵^*, Laura Bresson, PhD⁵^*, Ana-Leticia Maragno, PhD⁵^*, Caroline Liot, PharmD, PhD⁵^* and Andrew H Wei, MBBS, PhD, FRACP, FRCPA^3,6,7

¹The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
²Department of Medical Biology, The University of Melbourne, Melbourne, Australia
³The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
⁴Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia
⁵Oncology Research and Development Unit, Institut de Recherches Servier, Gif-sur-Yvette, France
⁶Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia
⁷The University of Melbourne, Melbourne, VIC, Australia

4137

Targeting PERK Arm of Unfolded Protein Response Helps to Eliminate Therapy-Induced Residual Senescent-like Acute Myeloid Leukemia Cells

Gowri Poigaialwar, PhD¹^*, Sumiko Takao, MD, PhD^2,3, Sovira Chaudhry, MSc⁴^*, Laura K. Schmalbrock, MD^2,3^*, Varun Gupta, PhD¹^*, Alex Kentsis, MD, PhD^2,3,5,6, Julio A. Aguirre-Ghiso, PhD⁷^*, Marina Konopleva, MD⁸, Maria S. Sosa, PhD⁹^* and Anna Skwarska, PhD⁴

¹Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, New York, NY
²Tow Center for Developmental Oncology, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
³Molecular Pharmacology Program, Sloan Kettering Institute, New York, NY
⁴Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY
⁵Departments of Pediatrics, Pharmacology and Physiology & Biophysics, Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY
⁶Memorial Sloan-Kettering Cancer Center, New York, NY
⁷Department of Cell Biology, Cancer Dormancy Institute, Montefiore Einstein Comprehensive Cancer Center, Gruss-Lipper Biophotonics Center, Albert Einstein College of Medicine, New York, NY
⁸Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY
⁹Department of Microbiology and Immunology, Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Cancer Dormancy Institute, Albert Einstein College of Medicine, New York, NY

4138

Type 2 Diabetes Leads to the Senescence of the Bone Marrow Microenvironment, and the Increase in DNA Damage Repair Function of AML Cells Mediates Anthracycline Resistance through Sasp

Yun Huang, MD, PhD¹^*, Xuejie Jiang, M.D.²^* and Zhiquan Long¹^*

¹Nanfang Hospital, Southern Medical University, Guangzhou, China
²Department of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

4139

Characterizing Secondary-Site Mutations in Isocitrate-Dehydrogenase-1 (IDH1)

Jyoti Kandarp¹^*, Arnold Kloos¹^*, Kerstin Goerlich¹^*, Nadine Kattre¹^*, Thomas Plenge¹^* and Michael Heuser, MD^1,2

¹Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany
²Department of Internal Medicine IV, University Hospital Halle (Saale), Halle (Saale), Germany

4140

Pharmacological Evaluation of a First-in-Class Hemoglobin Elevating Agent (HbEA) AND017 in a Mouse MDS Model of an Inducible Mutant c-Myc Knock-in

Gang Huang, PhD^1,2, Jie Bai¹^*, Mingzhe Pan¹^*, Dong Liu, PhD³^*, Min Xiong³^* and Shaojiang Deng, PhD³^*

¹Department of Cell Systems and Anatomy, UT Health San Antonio, San Antonio, TX
²Department of Pathology and Laboratory Medicine, UT Health San Antonio, San Antonio, TX
³Kind Pharmaceuticals, LLC, Redwood City, CA

4141

RGT-61159, Best-in-Class Small Molecule Inhibitor of MYB Via Selective RNA Splicing Alteration, Showed Robust Anti-Tumor Activity across AML Tumor Models Harboring Common Genetic Lesions

Norman Lu¹^*, Patricia Soulard¹^*, Ibrahim Kay¹^*, Kai Li¹^*, Xiubin Gu¹^*, Heather Sadlish¹^*, Jay Lee¹^*, Mariam Elhawary¹^*, Michael Rotelli¹^*, Sam Hasson¹^*, Thomas Wynn¹^*, Chris Yates¹^*, Zhiping Weng²^*, Simon Xi¹^* and Travis Wager, PhD¹^*

¹Rgenta Therapeutics, Woburn, MA
²University of Massachusetts Medical School, Worcester, MA

4142

BMS-986397, a First-in-Class Molecular Glue Degrader of Casein Kinase 1α (CK1α) for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Harboring Functional TP53

Carmen Jimenez¹^*, Sophie Peng²^*, Rama Krishna Narla²^*, Joshua Baughman³^*, Scott Wood²^*, Jean Lu⁴^*, Noelia Purroy⁵^*, Gina Yanochko⁶^*, Mark Nagy⁷^*, Gang Lu⁴^*, Mark Rolfe², Daniel W. Pierce⁸^* and Soraya Carrancio, PhD²^*

¹Bristol Myers Squibb, Seville, CA
²Research and Development, Bristol Myers Squibb, San Diego, CA
³Bristol-Myers Squibb, San Diego, CA
⁴GluBio Therapeutics, San Diego, CA
⁵Bristol Myers Squibb, San Francisco, CA
⁶Janssen Research & Development, San Francisco, CA
⁷Treeline Biosciences, Fairfax, VA
⁸Research and Development, Bristol Myers Squibb, Brisbane, CA

4143

The Bispecific Innate Cell Engager AFM28 Can Leverage AML Patient’s NK Cells in Addition to Allogeneic NK Cells, Enabling Elimination of CD123+ Leukemic Stem and Progenitor Cells in AML and MDS

Nanni Schmitt¹^*, Jana-Julia Siegler²^*, Alexandra Beck¹^*, Lea Hoppe¹^*, Mohammed Abba, MD¹^*, Alexander Streuer, MD¹^*, Stefan Klein, MD¹, Wolf-Karsten Hofmann, MD¹, Christian Merz²^*, Jens Pahl²^* and Daniel Nowak, MD¹^*

¹Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
²Affimed GmbH, Mannheim, Germany

4144

Targeting the IRE1α-XBP1s Pathway to Enhance Venetoclax Effectiveness in AML

Orsola Di Martino, PhD^1,2, Mary Basse¹^*, Nancy BJ Arthur, PhD³, Nishanth Gabriel, PhD¹^*, Judith Sokei, BPharm, MSc¹, Ahmed Mahmoud, MD³^*, Marco Vitale, MD⁴^*, Elena Masselli, MD²^*, Cecilia Carubbi, PhD²^*, Stephen Sykes, PhD⁵ and Francesca Ferraro, MD, PhD⁶

¹Department of Pediatrics, Division of Hematology-Oncology, Washington University of Saint Louis, School of Medicine, Saint Louis
²Department of Medicine and Surgery, University of Parma, Parma, Italy
³Department of Internal Medicine, Division of Oncology, Washington University of Saint Louis, School of Medicine, Saint Louis
⁴Vita-Salute University IRCSS San Raffaele, Milano, ITA
⁵Department of Pediatrics, Washington University School of Medicine, St Louis, MO
⁶Department of Internal Medicine, Division of Oncology, Washington University of Saint Louis, School of Medicine, SAINT LOUIS, MO

4145

Synergistic Effect of EZH2 Inhibitor Dznep and Flavonoid GL-V9 in AML through Inhibition Hells and Induction of DNA Damage

Chan Yang¹^*, Qinglong Guo²^*, Hui Hui²^*, Hui Li²^*, Chunhua Song, M.D., Ph.D.³ and Zheng Ge, MD, PhD¹

¹Department of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Institute of Hematology Southeast University, Nanjing, China
²State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China
³The Ohio State University, Columbus, OH

4146

BP1223, a Novel T Cell Engager Targeting CD39 for Potent Antitumor Activity in Acute Myeloid Leukemia

Junichiro Yuda, MD, PhD¹, Takahiko Aramaki, PhD²^*, Haruka Matsumura²^*, Kanto Nakajima, PhD²^* and Motoya Mie, PhD²^*

¹Department of Hematology and Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa-Shi, Chiba, Japan
²Kawasaki Research Laboratories, BrightPath Biotherapeutics Co.,Ltd., Kawasaki, Japan

4147

Pharmacodynamic Analysis of Mcl-1 and RNA Pol II^Ser2 Phosphorylation in Blasts from Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated on a Phase 1 Study of Venetoclax Plus Voruciclib

Nathalie Javidi-Sharifi, MD, PhD¹, Jeremy Zhang²^*, Sandra Wiley, PhD, MSc³, Richard G Ghalie, MD, MBA³, Alexey V. Danilov, MD, PhD⁴ and Matthew S. Davids, MD, MMSc⁵

¹Dana-Farber Cancer Institute, Boston
²Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
³MEI Pharma, San Diego, CA
⁴City of Hope National Medical Center, La Canada Flintridge, CA
⁵Dana-Farber Cancer Institute, Boston, MA

4148

Statins Kill Acute Myeloid Leukemia Cells through Low-Density Lipoprotein Receptor-Mediated Unfolded Protein Response Activation

Yohei Yasuda, MD¹^*, Yuta Fukui, MD²^*, Ken Morita, MD, PhD²^*, Muzhapaer Mubalizi, PhD³^*, Hiroki Hayashida, MD, PhD²^*, Toshiya Hino²^*, Yosuke Masamoto, MD, PhD^3,4 and Mineo Kurokawa, MD, PhD^2,4

¹Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Bunkyo-Ku, TKY, Japan
²Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
³Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, JPN
⁴Department of Cell Therapy and Transplantation Medicine, The University of Tokyo Hospital, Tokyo, Japan

4149

Proteolytic Control and Therapeutic Targeting of Oncogenic Gene Expression in Acute Myeloid Leukemia

Masahiro Uni, MD, PhD^1,2, Asher Preska Steinberg, PhD^2,3^*, Alicia Slavit^1,2^*, Sophia Rha^1,2^*, Shuyuan Cheng^1,2, Laura K. Schmalbrock, MD^1,2^*, Jiayu Su^4,5,6^*, Jing Ma, PhD⁷^*, Andrew McPherson, PhD³^*, Charles G. Mullighan, MBBS, MSc, MD⁷, Torsten Haferlach, MD⁸, Ilaria Iacobucci, PhD⁹, Jeffery M Klco, MD, PhD⁷, Raul Rabadan, PhD^4,5,10^* and Alex Kentsis, MD, PhD^1,2,11

¹Molecular Pharmacology Program, Sloan Kettering Institute, New York, NY
²Tow Center for Developmental Oncology, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
³Halvorsen Center for Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Program for Mathematical Genomics, Columbia University, New York, NY
⁵Department of Systems Biology, Columbia University, New York, NY
⁶New York Genome Center, New York, NY
⁷Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
⁸MLL Munich Leukemia Laboratory, Munich, Germany
⁹St. Jude Children's Research Hospital, Memphis, TN
¹⁰Department of Biomedical Informatics, Columbia University, New York, NY
¹¹Departments of Pediatrics, Pharmacology and Physiology & Biophysics, Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY

4150

APG-2449, a Novel Focal Adhesion Kinase (FAK) Inhibitor, Exhibits Antileukemic Activity and Enhances Lisaftoclax (APG-2575)-Induced Apoptosis in Acute Myeloid Leukemia (AML)

Zhou Yu, PhD¹^*, Zhiyan Liang, PhD²^*, Xinyi Yao, BS¹^*, Yanqiu Ji, BS¹^*, Dajun Yang, MD, PhD^1,2,3^* and Yifan Zhai, MD, PhD^1,2,4

¹Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China
²Ascentage Pharma Group Inc., Rockville, MD
³Department of Experimental Research, State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
⁴Guangzhou Healthquest Pharma Co., Ltd., Guangzhou, China

4151

AML Blasts Intrinsic Interferon Production Causes Resistance to Venetoclax in Human Acute Myeloid Leukemia Via Upregulation of MCL1, BCL2A1 and BCL-XL

Josephine Dubois¹^*, Kai Wu²^*, Darren King³^*, Xianing Zheng¹^*, Qianyi Ma¹^*, Karan Bedi¹^*, Jun Li¹^* and Sami N. Malek, MD⁴

¹University of Michigan, Ann Arbor
²UCSF, San Francisco
³Rogel Cancer Center, University of Michigan, Ann Arbor, MI
⁴Department of Medicine, University of Michigan Medical School, Ann Arbor, MI

4152

Specific Bone Marrow Niche Components Determine Degree of Protection from Gilteritinib Induced Differentiation Response in FLT3-ITD AML

Sophie C James¹^*, Samantha Atkinson^2,3^*, Richard Burt, PhD, FRCPath, MRCP^2,3,4^*, Cristina Lo Celso⁵^* and Paolo Gallipoli, MD¹

¹Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
²The Francis Crick Institute, London, United Kingdom
³Imperial College London, London, United Kingdom
⁴University College London Hospitals, London, United Kingdom
⁵Imperial College of London, London, United Kingdom

4153

Pharmacological Inhibition of METTL3 Enhances the Acute Myeloid Leukemia Cell Death Induced By Venetoclax Via the METTL3-YTHDF2-FBXW7-MCL1 Axis

Changqing Jiao¹^*, Chen Hu²^*, Mengya Pan¹^*, Junjie Zhou¹^*, Qingsong Liu²^* and Jian Ge¹^*

¹Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
²Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, China

4154

Loss of TET2 Creates a Distinct Immunopeptidome in Acute Myeloid Leukemia

Xiaorong Gu, PhD¹^*, Yahan Zhang, MS², Songa Bae¹^*, Dongxu Jiang, PhD², Daniel Vail, PhD²^*, Simon Schlanger, MS²^*, Jaroslaw Maciejewski¹ and Babal K. Jha, PhD^1,2

4155

Reactivation of p53 in TP53-Y220C Mutant AML: Mechanism of Action and Mechanism-Based Drug Combinations

Bing Z. Carter, PhD¹, Po Yee Mak¹^*, Baozhen Ke, BS¹^*, Xiaogang Wu²^*, Steffen Boettcher, MD³^*, Lauren B. Ostermann, BSc¹^*, Andrea Bedoy¹^*, Georgina Gener-Ricos, MD⁴^*, Jayastu Senapati, MD, DM, MBBS⁴, Courtney D. DiNardo, MD, MSc⁵, Anna Puzio-Kuter⁶^*, Arnold Levine⁷^* and Michael Andreeff, MD, PhD¹

¹Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
³Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Zurich, Switzerland
⁴Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁵Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX
⁶PMV Pharmaceuticals, Inc, Princeton, NJ
⁷Institute for Advanced Studies, Princeton

4156

Interferon Synergizes with Inhibition of Pro-Apoptotic Proteins to Reduce Leukemia Burden in PDX Models of ML-DS

Sonali P Barwe, PhD, MSc¹, Neha Bhagwat, PhD² and Anilkumar Gopalakrishnapillai, PhD, MSc³

¹Nemours Children's Hospital, Wilmington, DE
²Prelude Therapeutics Incorporated, Wilmington, DE
³Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders, Nemours Children's Hospital, Wilmington, DE

4157

Targeting Chronic Myeloid Leukemia with Potent and Specific BCR::ABL1 Degraders

Nataly Cruz-Rodriguez, PhD¹, Hua Tang, PhD²^*, Milad Rouhimoghadam, PhD¹^*, Junzhuo Liao, PhD²^*, Benjamin Bateman¹^*, Briana Bates, MS¹^*, Mario Pinzas¹^*, Xuhui Huang, PhD²^*, Weiping Tang, PhD²^* and Michael W. Deininger, MD, PhD^1,3

¹Versiti Blood Research Institute, Milwaukee, WI
²University of Wisconsin-Madison, Madison, WI
³Medical College of Wisconsin, Milwaukee, WI

4158

Integrated Stress Response Activation Induced By Usnic Acid Alleviates BCL-2 Inhibitor ABT-199 Resistance in Acute Myeloid Leukemia

Man Li^1,2^*, Jingjie Dong³^*, Yaonan Hong³^*, Li Jin²^*, Chengtao Sun²^*, Qi Liu³^*, Liqin Li²^*, Xiaoxiao Han²^*, Shengqian Deng²^*, Yue Feng²^*, Yiping Shen⁴^*, Guoyin Kai²^* and Dijiong Wu, MD, PhD⁴

¹Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
²Zhejiang Key TCM Laboratory for Chinese Resource Innovation and Transformation, School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China
³The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
⁴Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China

4159

Loss of TET2 Increases MHC Class I Expression in Acute Myeloid Leukemia

Xiaorong Gu, PhD¹^*, Songa Bae¹^*, Yahan Zhang, MS², Nakisha D Williams, MBBS¹^*, Dongxu Jiang, PhD², Simon Schlanger, MS²^*, Valeria Visconte, PhD³, Jaroslaw Maciejewski¹ and Babal K. Jha, PhD^1,2

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
²Center for Immunotherapy & Precision Immuno-Oncology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH
³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Taussig Cancer Institute, Cleveland, OH

4160

Effects of Magrolimab Therapy in Conjunction with Conventional Chemotherapeutics in Pediatric Acute Myeloid Leukemia Patient Derived Xenograft Models

Sohani K Sandhu¹^*, Julia G Kim²^*, Ritesh V Dontula²^*, Joshua J Cooper²^*, Jaden A Sherman²^*, Max P Rochette²^*, Lana E Kim¹^*, Michele S. Redell, MD¹ and Alexandra McLean Stevens, MD³

¹Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX
²Baylor College of Medicine / Texas Children's Hospital, Houston, TX
³Baylor College of Medicine/ Texas Children's Hospital, Bellaire, TX

4161

Using Structure-Based Modeling to Identify Effective Drug Combinations in RAS-Mutant Acute Myeloid Leukemia

Luke Jones, PhD^1,2, Oleksii Rukhlenko, PhD^1,2^*, Tânia Dias^1,2^*, Ciardha Carmody^1,2,3^*, Kieran Wynne²^*, Boris Kholodenko, PhD^1,2^* and Jonathan Bond, MD, PhD^1,2,4^*

¹School of Medicine, University College Dublin, Dublin, Ireland
²Systems Biology Ireland, Dublin, Ireland
³SFI Centre for Research Training in Genomics Data Science, Dublin, Ireland
⁴Children's Health Ireland at Crumlin, Dublin, Ireland

4162

Transient Menin Inhibition Is Sufficient to Induce Irreversible Polycomb-Mediated Silencing and Potent Anti-Proliferative Effects in MLL-Rearranged AML

Daniel Neville¹^*, Daniel Ferguson, PhD¹^*, Emily Heikamp, MD, PhD², Charles Bell, PhD³^*, Scott A Armstrong, MD, PhD⁴ and Omer Gilan⁵^*

¹Monash University, Clayton, VIC, Australia
²Dana Farber Cancer institute, Boston, MA
³University of Queensland, Brisbane, Australia
⁴Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
⁵Australian Centre for Blood Diseases, Monash University, Coburg, VIC, Australia

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH